Fibrosis, regeneration and cancer: what is the link? - PubMed (original) (raw)
Review
doi: 10.1093/ndt/gfr567. Epub 2011 Nov 18.
Affiliations
- PMID: 22102616
- DOI: 10.1093/ndt/gfr567
Review
Fibrosis, regeneration and cancer: what is the link?
Valeria Cernaro et al. Nephrol Dial Transplant. 2012 Jan.
Abstract
Tubulo-interstitial fibrosis constitutes the final common pathway for all pathological conditions that evolve towards chronic kidney disease, and transforming growth factor-β1 plays a key role in this process. Furthermore, neutrophil gelatinase-associated lipocalin appears not only to be a simple marker of renal injury but also an active player in disease progression. We are not yet able to control and modulate this phenomenon. Therefore, a better understanding of fibrogenic molecular mechanisms is necessary to detect possible therapeutic strategies that interfere with fibrosis and then stop the progression of renal disease. The line of research called 'regenerative medicine' works toward this. According to many authors, the formation of a fibrotic extracellular matrix disrupts the cells' polarity and stimulates their proliferation, creating conditions for cancer development. However, there is another plausible hypothesis: is it possible that fibrosis provides a sort of 'protection' from the development of a cancer as a consequence of the intense proliferation that characterizes any inflammatory process? In superior organisms, and also in humans, regeneration may have been selected negatively and replaced by fibrosis in the course of evolution, to warrant species survival: in fact, unchecked pluripotent cell production and proliferation can lead to tumour development and the potential death of a single individual. Hence, tumours might be the outcome of the failure of fibrotic processes, most likely due to some mediators predominating over others. So, valid experimental models are necessary to understand the interactions that exist between fibrosis and tumours and to evaluate the real advantage of therapies that aim to inhibit the fibrotic process at the renal level or that of other organs. The ideal approach would be to limit fibrosis and then organ function loss but without exposing the patient to risks of developing a tumour, starting from as early as the drugs prescribed.
Similar articles
- [Regeneration following acute kidney damage].
De Broe ME. De Broe ME. Verh K Acad Geneeskd Belg. 1998;60(4):359-83; discussion 383-4. Verh K Acad Geneeskd Belg. 1998. PMID: 9883082 Dutch. - Liver fibrosis: from the bench to clinical targets.
Pinzani M, Rombouts K. Pinzani M, et al. Dig Liver Dis. 2004 Apr;36(4):231-42. doi: 10.1016/j.dld.2004.01.003. Dig Liver Dis. 2004. PMID: 15115333 Review. - Cytokines in epithelial-mesenchymal transition: a new insight into obstructive nephropathy.
Bani-Hani AH, Campbell MT, Meldrum DR, Meldrum KK. Bani-Hani AH, et al. J Urol. 2008 Aug;180(2):461-8. doi: 10.1016/j.juro.2008.04.001. Epub 2008 Jun 11. J Urol. 2008. PMID: 18550128 Review. - Progression in chronic kidney disease.
Eddy AA. Eddy AA. Adv Chronic Kidney Dis. 2005 Oct;12(4):353-65. doi: 10.1053/j.ackd.2005.07.011. Adv Chronic Kidney Dis. 2005. PMID: 16198274 Review. - Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition.
Guarino M, Tosoni A, Nebuloni M. Guarino M, et al. Hum Pathol. 2009 Oct;40(10):1365-76. doi: 10.1016/j.humpath.2009.02.020. Epub 2009 Aug 19. Hum Pathol. 2009. PMID: 19695676 Review.
Cited by
- Unveiling correlations between aristolochic acids and liver cancer: spatiotemporal heterogeneity phenomenon.
Li C, Li X, Niu M, Xiao D, Luo Y, Wang Y, Fang ZE, Zhan X, Zhao X, Fang M, Wang J, Xiao X, Bai Z. Li C, et al. Chin Med. 2024 Sep 28;19(1):132. doi: 10.1186/s13020-024-01003-y. Chin Med. 2024. PMID: 39342223 Free PMC article. Review. - Comparative molecular analysis of oral submucous fibrosis and other organ fibrosis based on weighted gene co-expression network analysis.
Chen J, Liu B, Xie X, Li W. Chen J, et al. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Dec 28;47(12):1663-1672. doi: 10.11817/j.issn.1672-7347.2022.220452. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022. PMID: 36748376 Free PMC article. - Multi-functional gene ZNF281 identified as a molecular biomarker in soft tissue regeneration and pan-cancer progression.
Hou X, Luan J, Fu S. Hou X, et al. Front Genet. 2023 Jan 5;13:1082654. doi: 10.3389/fgene.2022.1082654. eCollection 2022. Front Genet. 2023. PMID: 36685971 Free PMC article. - STING Suppresses Mitochondrial VDAC2 to Govern RCC Growth Independent of Innate Immunity.
Zhu Z, Zhou X, Du H, Cloer EW, Zhang J, Mei L, Wang Y, Tan X, Hepperla AJ, Simon JM, Cook JG, Major MB, Dotti G, Liu P. Zhu Z, et al. Adv Sci (Weinh). 2023 Jan;10(3):e2203718. doi: 10.1002/advs.202203718. Epub 2022 Nov 29. Adv Sci (Weinh). 2023. PMID: 36445063 Free PMC article. - Inhibitory Effects of Rhein on Renal Interstitial Fibrosis via the SHH-Gli1 Signal Pathway.
Luo Y, Jiang J, Cheng J, Xuan C, Xiong Y, Xiong W, Cao W, Li Y. Luo Y, et al. Evid Based Complement Alternat Med. 2022 Aug 5;2022:4398265. doi: 10.1155/2022/4398265. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35966731 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical